(Press-News.org) BOSTON – June 5, 2014 - People with type 1 diabetes who have developed kidney complications can slow the progression of their complications by improving control of their glycemic (blood glucose) levels over the long term.
This finding, which may change clinical practice at many institutions for this population, was drawn from a long-term observational study led by Andrzej Krolewski, M.D., Ph.D., head of Joslin Diabetes Center's Section on Genetics and Epidemiology.
Running for almost 20 years, the study showed that "you have to improve glycemic control for a long period of time to see this effect among these patients," emphasized Krolewski, who is also a professor of medicine at Harvard Medical School.
Published in the Journal of the American Society of Nephrology, the study followed a cohort of type 1 diabetes patients in the Joslin Clinic who had developed proteinuria. (Proteinuria is a potential kidney complication in which urine contains elevated amounts of protein; albumin is typically the most common protein found). The condition frequently leads to end-stage renal disease (ESRD), a life-threatening ailment that can only be treated with kidney dialysis or transplant.
The Joslin study began tracking kidney impairment among the patients in 1991 and followed them until 2011. As part of the study, researchers collected measurements of glycolated hemoglobin (HbA1c), which provides an indication of average blood glucose levels, for 279 patients.
All patients with type 1 diabetes produce little or none of the hormone insulin, and depend on insulin injections to stay alive. To maintain their health and minimize kidney problems and other complications, they must actively control their glycemic levels by paying attention around the clock to their blood glucose levels, diet and exercise. Endocrinologists generally recommend an HbA1c goal of 7.0% or below, but achieving that level of control is difficult. The patients with proteinuria in the study were generally poorly controlled, with an average HbA1C of 9.3% before the study began.
Earlier investigations had suggested that achieving better glycemic control did not slow kidney complications for such patients. However, those studies were small and only extended for several years. In contrast, the Joslin research showed that those who lowered their HbA1C levels demonstrated a significantly lower risk of ESRD after a lag period of about five years. After 15 years, those with improved glycemic control had a cumulative risk of ESRD of 29% while those whose HbA1c increased or remained poor had a risk of 42%. There were no detectable differences between these two groups at the start of the study.
"The number of patients with diabetic kidney disease continues to grow at an epidemic rate throughout the rest of the world," said Robert Stanton, M.D., chief of the Kidney and Hypertension Section at Joslin and coauthor on the paper. "There is a great need to find new approaches and new treatments to both prevent development of diabetic kidney disease and to slow progression. This long-term study provides an important rationale to both patients and doctors to improve glycemic management in people with type 1 diabetes and kidney disease and to work very hard to maintain the glycemic control over many years."
Importantly, patients with proteinuria could substantially postpone severe outcomes from the disease without maintaining optimal HbA1c levels, Krolewski said. "We are talking about improving HbA1c from 11% to 9%, or 10% to 8%," he said, adding that earlier work by his lab indicated that levels of HbA1c below 8-9% may be sufficient to avoid kidney damage.
Down the road, Krolewski has high hopes for the emergence of "smart insulins," which have been modified to automatically release the hormone once blood glucose levels rise above certain levels. When and if these drugs become available, he speculated, they might prove highly effective for slowing down progression to ESRD among this group of patients even if the drugs maintain higher than ideal glycemic levels.
Most people with type 1 diabetes will never proceed to ESRD, even if their glycemic control is far from perfect. Among the estimated 80,000 in the United States who have developed proteinuria, Krolewski said, about 10% are "rapid progressors" whose kidney function deteriorates completely within a few years.
Examining risk factors in developing kidney disease, researchers in his lab found in 2012 that high concentrations of the proteins TNFR1 and TNFR2 in blood accurately predict the risk of kidney function loss in both type 1 and type 2 diabetes 10 years in advance. This work has been licensed to EKF Diagnostics, a European firm now developing a commercial diagnostic test. Eventually, Joslin scientists hope, tests will identify diabetes patients at risk of impaired kidney function. Those patients then can be given special efforts to improve their glycemic control, and perhaps eventually also receive new combinations of drugs tailored to their condition.
Changes in clinical practice are usually driven by clinical trials, which compare results for multiple groups of patients who receive different treatments, rather than by observational investigations such as the Joslin proteinuria study. Krolewski noted, however, that a prospective clinical trial cannot be designed to address questions about effects of improved long-term glycemic control on progression to ESRD since it would not be ethically appropriate to purposely maintain a control group of patients with very high levels of blood glucose.
Other contributors to the study included Jan Skupien, James Warram and Adam Smiles from Joslin and Andrzej Galecki from the University of Michigan.
This research was funded by JDRF as part of its program to develop therapies that progressively treat and reverse debilitating complications resulting from the impact of type 1 diabetes throughout the body. "These findings provide hope that long-term improvements in glucose control may alter the course of kidney disease in people with type 1 diabetes," said JDRF program director Helen Nickerson, Ph.D. "This reinforces the importance of improved glycemic control as we pursue novel therapies to slow or reverse loss of kidney function." The National Institutes of Health provided additional funding for the work.
INFORMATION:
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education and care.
Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org.
About Joslin Research
Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30‐plus faculty‐level investigators, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit http://www.joslinresearch.org.
About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. As the largest charitable supporter of T1D research, JDRF is currently funding $568 million in scientific research in 17 countries.
Improved glucose control slows progression to end-stage renal disease in type 1 diabetes
2014-06-06
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
For forests, an earlier spring than ever
2014-06-06
Every spring, as the weather warms, trees in forests up and down the east coast explode in a bright green display of life as leaves fill their branches, and every fall, those same leaves provide one of nature's great color displays of vivid yellow, orange and red.
Over the last two decades, spurred by higher temperatures caused by climate change, Harvard scientists say, forests throughout the Eastern U.S. have experienced earlier springs and later autumns than ever before.
Using a combination of satellite imagery, tower-mounted instruments and on-the-ground observations, ...
Study finds public awareness of head and neck cancers low
2014-06-05
Bottom Line: Public awareness of head and neck cancer (HNC) is low, with few Americans knowing much about risk factors such as tobacco use and human papillomavirus (HPV).
Author: Alexander L. Luryi, B.S., of the Yale University School of Medicine, New Haven, Conn.
Background: HNC is the 10 th most common cancer in the United States. It is a potentially preventable disease with about 75 percent of cases caused by tobacco use. In recent years, HPV has been established as a risk factor for HNC. Increased public awareness of HNC and its risk factors could help improve ...
Scientists find new targets that could increase effectiveness of breast cancer treatments
2014-06-05
JUPITER, FL, June 5, 2014 – Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable side effects associated with current treatments.
The study was published online ahead of print on June 5, 2014 by the journal Structure.
Approximately two out of three breast cancers are driven by receptors that bind the hormones estrogen and progesterone—when the hormones bind to these receptors in cancer cells, ...
Researchers at the Gladstone Institutes find novel approach to reactivate latent HIV
2014-06-05
SAN FRANCISCO, CA–June 5, 2014–A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection. They discovered that increasing the random activity, or noise, associated with HIV gene expression–without increasing the average level of gene expression–can reactivate latent HIV. Their findings were published today in the journal Science.
When HIV infects an immune cell, it inserts its genetic material into the DNA of the infected cell. In ...
Demographics drive fitness partner decisions online, Penn study finds
2014-06-05
Who would you rather have as a fitness partner: a paragon of athleticism and dedication who could motivate you to exceed your current level of fitness or an equal, with whom you could exchange tips and encouragement on the road to better health?
Or neither? According to a new study led by University of Pennsylvania's Damon Centola, participants in an online fitness program ignored the fitness aptitude of their potential partners.
"Instead they chose contacts based on characteristics that would largely be observable in regular, offline face-to-face networks: age, gender ...
New tuberculosis test more than skin deep
2014-06-05
A new screening process for tuberculosis (TB) infections in Canadian prisons could mean that more than 50 per cent of those screened won't undergo unnecessary treatment due to false positives.
According to research by Wendy Wobeser and medical resident Ilan Schwartz, a test for TB using interferon-gamma release assays (IGRA) will detect a pre-existing TB infection, or latent TB, that might not present itself for many years, or until the body becomes weakened by another source.
"It's fairly uncommon that latent TB will reactivate – only about a 10 per cent chance," says ...
Seemingly invincible cancers stem cells reveal a weakness
2014-06-05
CAMBRIDGE, Mass. (June 5, 2014) – Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs. Now, however, researchers at Whitehead Institute have identified a critical weakness that actually exploits one of these cells' apparent strengths—their ability to move and invade tissues.
"This is the first vulnerability of invasive cancer cells that we really understand," says Whitehead Member Piyush Gupta, whose lab's latest work is described in the June issue of the journal ...
New evidence links air pollution to autism, schizophrenia
2014-06-05
A new study published in the journal Environmental Health Perspectives describes how exposure to air pollution early in life produces harmful changes in the brains of mice, including an enlargement of part of the brain that is seen in humans who have autism and schizophrenia.
As in autism and schizophrenia, the changes occurred predominately in males. The mice also performed poorly in tests of short-term memory, learning ability, and impulsivity.
The new findings are consistent with several recent studies that have shown a link between air pollution and autism ...
New findings out on brain networks in children at risk for mental disorders
2014-06-05
DETROIT – Attention deficits are central to psychiatric disorders such as schizophrenia or bipolar disorder, and are thought to precede the presentation of the illnesses. A new study led by Wayne State University School of Medicine researcher Vaibhav Diwadkar, Ph.D. suggests that the brain network interactions between regions that support attention are dysfunctional in children and adolescents at genetic risk for developing schizophrenia and bipolar disorder.
"The brain network mechanisms that mediate these deficits are poorly understood, and have rarely been tackled ...
Rice developing mobile DNA test for HIV
2014-06-05
Rice University bioengineers are developing a simple, highly accurate test to detect signs of HIV and its progress in patients in resource-poor settings.
The current gold standard to diagnose HIV in infants and to monitor viral load depends on lab equipment and technical expertise generally available only in clinics, said Rice bioengineer Rebecca Richards-Kortum. The new research features a nucleic acid-based test that can be performed at the site of care.
Richards-Kortum, director of the Rice 360˚: Institute for Global Health Technologies, and her colleagues reported ...